📈 Small stock breakout 📈

Uptrend in a down market                                                                                                                                                                                                                                                                                                                                                                                                                 April 22, 2024 📈 Small stock breakout 📈 Uptrend in a down market 📈 Join us for LIVE TRADING action all day long 📈 Join hundreds of us for LIVE TRADING action all day long in the [Market Master’s trading room](. Talk about today’s focus stock, plus dozens of other breaking stocks that are moving during the day. We have been on a rocky ride for the market over the last couple of weeks since I pointed out that we were finally entering a downtrend on the daily charts. Things move very quickly in this market, so you need to be able to spot trends and react to them very quickly.  I think we are going to see some bottom feeders come in this week, and the market will probably move higher… but don’t get too comfortable! I am still finding incredible opportunities with momentum stocks right now. Just like my last idea on Thursday, that rallied 25% the first day and then came back with another 30% during the following day. If you look at pockets of the market where things are already heating up, you can avoid a lot of the pain and struggles of trying to trade large-cap tech stocks right now. So, while the market has a little steam this morning, I think it is a great opportunity to get back to work and hunt for new ideas! Right now, I want you to pull up Tiziana Life Sciences (TLSA) on your platform. If you’re like me, the first thing you’ll notice is that it is hard not to type in “TSLA,” which is Tesla, of course. We have all been hard-wired to do that over the years. Since you probably did look at the car company first, you’ll notice that stock has lost about 20% over the last week. TLSA (the correct stock below) is the exact opposite right now. This is an absolutely beautiful chart right now. TLSA has managed to breakout 20% higher over the last week, which I thought was incredibly impressive considering that we just saw the largest stock market losses in a long time. After a long base, the stock decided that as the market was dumping, it was finally time to wake up and start to move higher. I have pointed out this strange type of move several times recently. For some weird reason, I see a lot of stocks that traders have given up on making a move higher when the market moves lower.  For whatever reason, you can pretty clearly see the “Gamma Trigger” move that signaled a few days ago with the double “GO” signals and a break back above the 20-hour moving average. That move then led to a significant move to the upside. It could be because the company has been issuing some fantastic news lately. In fact, just this morning, [you can read]( that they just announced tremendous results for patients in their clinical study. With an oversold stock like this, it sure doesn’t take much positive news to get things turning in the right direction again. I think this is an excellent idea to look at right now. With all of the crazy volatility in the market, I prefer to avoid it and narrowly focus on short-term ideas that seem to be working. As long as the trend stays above that 20-hour level I showed you in the chart above, I think this is a really good stock to consider right now. It is hard to find any pockets of positive momentum right now, so I think TLSA is presenting us with a great opportunity today. As a small biotech company, there is obviously a lot to digest about the business side of things as well. So let’s dive deeper into what this company does. TLSA is a clinical-stage biopharmaceutical company developing breakthrough therapies for neuroinflammatory and neurodegenerative diseases with high unmet needs. Its lead candidate, Foralumab, is a monoclonal antibody therapy that reduces inflammation by targeting a protein on T cells called CD3. One of TLSA’s key innovations is administering Foramulab intranasally, which produces minimal toxicity while creating local T cells that more easily cross the blood-brain barrier. The upshot is that Foramulab may help suppress the activation of the brain’s most prominent immune cells — called “microglial cells” — which are overactive in diseases such as multiple sclerosis and Alzheimer’s. While there are other therapies that target CD3, Foralumab is the only CD3-targeting monoclonal antibody that is “fully human.” In theory, this should minimize adverse immune responses. A similar anti-CD3 molecule that is only “humanized,” Teplizumab, was [recently acquired]( by French pharma giant Sanofi for $2.9 billion. Already, Foramulab has shown incredible promise in reducing microglial activation. Just this past week, TLSA [presented data]( at the annual meeting of the American Academy of Neurology showing that nasal Foramulab “exhibited a reduction in microglial activation and disease stabilization in non-active secondary progressive multiple sclerosis [SPMS] patients … as observed through positron emission tomography (PET) imaging.” Even more importantly, “clinically relevant improvements were observed in patient-reported outcomes, including stability … and improvements in fatigue levels.” Dr. Tarun Singhal, an associate professor at Harvard Medical School, authored the study, noting that it “provides initial evidence that this fully human anti-CD3 has the potential to benefit this type of MS, which is the most difficult form to treat.” Based on population prevalence data, TLSA estimates there are 94,000 SPMS patients in the US 155,000 in the EU. But that form of multiple sclerosis isn’t the only potential indication for Foramulab. TLSA has also received [Investigational New Drug]( clearance from the FDA for Foramulab as a treatment for Alzheimer’s, and it is also [investigating]( the therapy for Long Covid, which is estimated to cost the US healthcare system almost $2.6 trillion. TLSA’s pipeline Dr. Howard Weiner, a professor of neurology at Harvard Medical School and the director and founder of the Partners Multiple Sclerosis Center notes that, “We have now seen the potential of intranasal foralumab to dampen microglial activation in three major neuroinflammatory-related diseases, which creates significant optionality for exploring its benefits in some of the most important and burdensome medical conditions of our time.” Spend time right now doing your own research on the stock, and of course, always approach your trading in a responsible manner. Trading is very risky and nothing is ever guaranteed, so never trade with more than you can afford to lose, and always have a well-thought-out game plan that takes your personal risk tolerance into consideration. Bottom line: While the stock market is likely to move higher over the next few days, it will be very volatile. I think it makes a lot of sense to focus on smaller stocks that have been bucking the downtrend and finding strength. TLSA fits the bill perfectly right now. Make sure you keep TLSA on the top of your list today. To Your Success, Jeff Bishop 👊 Make sure you are getting my mobile text alerts –  text “RAGE” to 1-(888) 404-5747 to get all of my latest HOT STOCK ideas delivered right to your phone (make sure you put the “1” at the front!). Don’t miss out! If you have difficulty reading the disclaimer above, you can [visit this page]( for the full details. Update your email preferences or unsubscribe [here]( © 2024 Jason Bond Picks 62 Calef Hwy. #233 Lee, NH 03861, United States of America